Appraisal of Therapeutic Impact of One Round of Mass Praziquantel Administration (MPA) on Urinogenital Schistosomiasis in Benue State, Nigeria

Okete James Agada; Oku Enewan Esien; Asor Joseph Ele; Eme Effiong Etta

doi:doi:10.11648/j.ajcem.20221001.12

| Peer-Reviewed

Appraisal of Therapeutic Impact of One Round of Mass Praziquantel Administration (MPA) on Urinogenital Schistosomiasis in Benue State, Nigeria

Okete James Agada, Oku Enewan Esien, Asor Joseph Ele, Eme Effiong Etta

Published in American Journal of Clinical and Experimental Medicine (Volume 10, Issue 1)

Received: 30 June 2021 Accepted: 19 July 2021 Published: 24 January 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Preventive chemotherapy through mass administration of praziquantel is the current global schistosomiasis control strategy recommended by the World Health Organization (WHO). We aimed to assess therapeutic impact of one round of mass praziquantel treatment on prevalence and intensity of Schistosoma haematobium infection. Longitudinal studies were carried out between March and November, 2018 in Katsina-Ala, Benue State, Nigeria following one round of mass praziquantel administration by the NTDs unit of CDC, Benue State in December, 2017. A total of 3,810 pupils, aged 5-19 years old were recruitedat baseline. Prevalence and intensity were determined using standard laboratory procedures for three successive phases (phase 1- three months; phase 2- six months and phase 3- nine months post treatment periods). Overall treatment coverage was 64.86%. Prevalence of infection was recorded in all the 3 phases, with the first phase having the highest prevalence (12.30%) followed by the third phase (9.12%) and the second phase (7.60%), the difference been significant (P < 0.05). The highest intensity of infection (16 ova/ 10 ml urine) was observed in the first phase, followed by the third phase (15.10 ova/10 ml urine) and the second phase (11 ova/ 10 ml urine). More males were infected than females. Prevalence and intensity were higher in untreated pupils than treated pupils in all the survey phases. The studies therefore, call for repeated mass treatment and integrated control measures to be adopted for total elimination of schistosomiasis.

Published in	American Journal of Clinical and Experimental Medicine (Volume 10, Issue 1)
DOI	10.11648/j.ajcem.20221001.12
Page(s)	8-14
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Mass Praziquantel Administration, Therapeutic Impact, Urinogenital Schistosomiasis, Nigeria

References

[1]	Abdoulaye, D., Boubacar, B. Bourema, K., Oumar, S. and Ogoara, D. (2015). Factors associated with coverage of praziquantel for schistosomiasis control in the community-directed intervention (CDI) approach in Mali, West Africa. InfectiousDisease of Poverty, 2: 11-22.
[2]	Abdullahi, M. K., Bassey, S. E. and Oyeyi, T. I. (2011). The epidemiology of Schistosoma haematobium infection in the 14 Local Government Areasof Kano State, Nigeria, Research Journal of Parasitology, 32: 19-24.
[3]	AdamuT. (2015). Schistosomiasis in Wurno district of Sokoto State, Nigeria. Nigeria Journal of Parasitology, 22 (2): 81-84.
[4]	Amali, O. (1988). Studies on the epidemiology of urinary schistosomiasis and the ecology of its snail host in Benue State, Nigeria. Unpublished Ph.D thesis, University of Ibadan.
[5]	Anosike, J. C., Okere, A. W., Nwoke, B. E., Chukwu, J. U., Nosu, D. C. and Obasi, C. U. (2003). Endemicity of vessical schistosomiasis in the Ebonyi- Benue river valley, South East Nigeria. International Journal of Hygiene and Environmental Health, 206 (3), 205-210.
[6]	Anyanwu, G. I. and Okoro, O. C. (2002). Observations on urinary schistosomiasis in school childrenin Abia State, Nigeria. Journal of Exoerimental Health and Human Development, 3 (1), 31-34.
[7]	Asor, J. E. and Arene, F. O. (2010). Prevalence and intensity of S. haematobium in Odau community in the Niger Delta, Nigeria. Mary Slessor Journal of Medicine, 10 (1), 59-69.
[8]	Bassey, J. P. A. (2012). The spatial distribution of urinary shistosomiais in the federal Capital territory using Geographical Information System and Satellite imagery. Unpublished Ph.D thesis, University of Calabar, Calabar, Nigeria.
[9]	Bruno, T. and Omar, T. (2016). Impact of annual praziquantel treatment on urogenital schistosomiasis in seasonal transmission seasons foci in central Senegal, Neglected Tropical Diseases, 10 (3), 10-16.
[10]	Etim, S. E., Okon, O. E., Oku, E. E., Ukpong, G. I., Ohiama, M. E. and Uttah, C. E. (2012). Urinary schistosomiasis in Rice–Farming community in Biase Area of Cross River State, Nigeria. Nigerian Journal of Parasitology, 33 (2): 197-201.
[11]	Global Burden of Disease (GBD) Collaborative Network (2016). Global Burdenof Disease Study 2016 Results. Seattle: Institute for Health Metrics and Evaluation (IHME); 2017.
[12]	Houmsuo, R. S., Kela, S. L. and Suleiman, M. M. (2011). Performance of microhaematuria and protinuria as measured by urine reagent strips in estimating intensity and prevalence of Schistosoma haematobium in Nigeria. Asian Pacific Journal of Tropical Medicine, 997-1000.
[13]	Humphries, D., Nguyen, S., Boakye, D., Wilson, M. and Cappello, M. (2012). The promise and pitfalls of mass drug administration to control intestinal helminth infections. Journal of Infect Diseases, 25, 584–9.
[14]	Isaac, O. O. Pauline, N. M., Goeffrey, M. and Kennedy, A. (2016). Impact of two rounds of Praziquantel mass drug administration on Schistosoma mansoni infection prevalence and intensity: a comparison between community wide treatment and school based treatment in Western Kenya. International Journal of Parasitology, 46 (7), 439-445.
[15]	Ismail, M., Botros, S., Mettwally, A., William, S., Farghaly, A., Tao, L.-F., Day, T. A. and Bennet, J. L. (1999). Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. American Journal of Tropical Medicine and Hygiene, 60, 932-935.
[16]	Nawal, M. N (2010) Schistosomiasis: Health Effects on Women. Reviews inObstetrics and Gynecology, 3: 28-32.
[17]	NationalSchistosomiasis Control Program (NSCP) (1991). Schistsosomiasis news. Lagos: Federal Ministry of Health, 146. 37-43.
[18]	Okete, J. A., Edu, E. A. & Oku, E. E. (2015). Efficacy of the ethanol extracts of Talinumtriangulare (Jacq) for control of the freshwater snail, Bulinusglobosus, the vector of urinary schistosomiasis. International Journal of Pure and Applied Zoology, 3 (1): 76-86.
[19]	Red Urine Study Group (1995). Identification of highrisk communities for Schistosomiasis in Africa. A Multi-Country study. Social and Environmental Research project Report, 3, 34-40.
[20]	Taylor, P. & Makura, O. (2009). Prevalence and distribution of schistosomiasis in Zimbabwe. Annals of tropical Medicine and Parasitology, 79, 287-299.
[21]	The Carter Center (2010). The Carter Center for Schistosomiasis (Bilharziasis) Control and Prevention. http://www.cartercenter.org/health/schistosomiasis/treatment.html?printerfriendly-true. Accessed 23^rd September, 2018.
[22]	Wilkinse, H. A., Goll, P. H., Marshall, T. F. & Moore, P. J. (1979). The significance of proteinuria and haematuria in Schistosoma haematobium infection. Transactions of the Royal Society of Tropical Medicine and Hygiene, 9, 74-80.
[23]	World HealthOrganization (2016). Preventive Chemotherapy in human helminthiasis: coordinated use of antiheminthic drugs in control interventions: A manual for health professionals and programme managers, WHO Press, Geneva, Switzerland, pp 1-74.
[24]	World Health Organization (2006). Shistosomiasis and water resources development: World Health Organization (1995). Health of school – aged children: treatment of intestinal helminthiasisand schistosomiasis. WHO/SCISTO/95.112.WHO/ CDS/95.1, Geneva.

Cite This Article

Plain Text BibTeX RIS

APA Style

Okete James Agada, Oku Enewan Esien, Asor Joseph Ele, Eme Effiong Etta. (2022). Appraisal of Therapeutic Impact of One Round of Mass Praziquantel Administration (MPA) on Urinogenital Schistosomiasis in Benue State, Nigeria. American Journal of Clinical and Experimental Medicine, 10(1), 8-14. https://doi.org/10.11648/j.ajcem.20221001.12

Copy | Download

ACS Style

Okete James Agada; Oku Enewan Esien; Asor Joseph Ele; Eme Effiong Etta. Appraisal of Therapeutic Impact of One Round of Mass Praziquantel Administration (MPA) on Urinogenital Schistosomiasis in Benue State, Nigeria. Am. J. Clin. Exp. Med. 2022, 10(1), 8-14. doi: 10.11648/j.ajcem.20221001.12

Copy | Download

AMA Style

Okete James Agada, Oku Enewan Esien, Asor Joseph Ele, Eme Effiong Etta. Appraisal of Therapeutic Impact of One Round of Mass Praziquantel Administration (MPA) on Urinogenital Schistosomiasis in Benue State, Nigeria. Am J Clin Exp Med. 2022;10(1):8-14. doi: 10.11648/j.ajcem.20221001.12

Copy | Download

@article{10.11648/j.ajcem.20221001.12,
  author = {Okete James Agada and Oku Enewan Esien and Asor Joseph Ele and Eme Effiong Etta},
  title = {Appraisal of Therapeutic Impact of One Round of Mass Praziquantel Administration (MPA) on Urinogenital Schistosomiasis in Benue State, Nigeria},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {10},
  number = {1},
  pages = {8-14},
  doi = {10.11648/j.ajcem.20221001.12},
  url = {https://doi.org/10.11648/j.ajcem.20221001.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20221001.12},
  abstract = {Preventive chemotherapy through mass administration of praziquantel is the current global schistosomiasis control strategy recommended by the World Health Organization (WHO). We aimed to assess therapeutic impact of one round of mass praziquantel treatment on prevalence and intensity of Schistosoma haematobium infection. Longitudinal studies were carried out between March and November, 2018 in Katsina-Ala, Benue State, Nigeria following one round of mass praziquantel administration by the NTDs unit of CDC, Benue State in December, 2017. A total of 3,810 pupils, aged 5-19 years old were recruitedat baseline. Prevalence and intensity were determined using standard laboratory procedures for three successive phases (phase 1- three months; phase 2- six months and phase 3- nine months post treatment periods). Overall treatment coverage was 64.86%. Prevalence of infection was recorded in all the 3 phases, with the first phase having the highest prevalence (12.30%) followed by the third phase (9.12%) and the second phase (7.60%), the difference been significant (P < 0.05). The highest intensity of infection (16 ova/ 10 ml urine) was observed in the first phase, followed by the third phase (15.10 ova/10 ml urine) and the second phase (11 ova/ 10 ml urine). More males were infected than females. Prevalence and intensity were higher in untreated pupils than treated pupils in all the survey phases. The studies therefore, call for repeated mass treatment and integrated control measures to be adopted for total elimination of schistosomiasis.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Appraisal of Therapeutic Impact of One Round of Mass Praziquantel Administration (MPA) on Urinogenital Schistosomiasis in Benue State, Nigeria
AU  - Okete James Agada
AU  - Oku Enewan Esien
AU  - Asor Joseph Ele
AU  - Eme Effiong Etta
Y1  - 2022/01/24
PY  - 2022
N1  - https://doi.org/10.11648/j.ajcem.20221001.12
DO  - 10.11648/j.ajcem.20221001.12
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 8
EP  - 14
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20221001.12
AB  - Preventive chemotherapy through mass administration of praziquantel is the current global schistosomiasis control strategy recommended by the World Health Organization (WHO). We aimed to assess therapeutic impact of one round of mass praziquantel treatment on prevalence and intensity of Schistosoma haematobium infection. Longitudinal studies were carried out between March and November, 2018 in Katsina-Ala, Benue State, Nigeria following one round of mass praziquantel administration by the NTDs unit of CDC, Benue State in December, 2017. A total of 3,810 pupils, aged 5-19 years old were recruitedat baseline. Prevalence and intensity were determined using standard laboratory procedures for three successive phases (phase 1- three months; phase 2- six months and phase 3- nine months post treatment periods). Overall treatment coverage was 64.86%. Prevalence of infection was recorded in all the 3 phases, with the first phase having the highest prevalence (12.30%) followed by the third phase (9.12%) and the second phase (7.60%), the difference been significant (P < 0.05). The highest intensity of infection (16 ova/ 10 ml urine) was observed in the first phase, followed by the third phase (15.10 ova/10 ml urine) and the second phase (11 ova/ 10 ml urine). More males were infected than females. Prevalence and intensity were higher in untreated pupils than treated pupils in all the survey phases. The studies therefore, call for repeated mass treatment and integrated control measures to be adopted for total elimination of schistosomiasis.
VL  - 10
IS  - 1
ER  -

Copy | Download

Author Information

Okete James Agada

Department of Zoology, Federal University of Agriculture Makurdi, Makurdi, Nigeria
Oku Enewan Esien

Department of Zoology & Environmental Biology, University of Calabar, Calabar, Nigeria
Asor Joseph Ele

Department of Zoology & Environmental Biology, University of Calabar, Calabar, Nigeria
Eme Effiong Etta

Department of Animal and Environmental Biology, Cross River State University of Technology, Calabar, Nigeria

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Okete James Agada, Oku Enewan Esien, Asor Joseph Ele, Eme Effiong Etta. (2022). Appraisal of Therapeutic Impact of One Round of Mass Praziquantel Administration (MPA) on Urinogenital Schistosomiasis in Benue State, Nigeria. American Journal of Clinical and Experimental Medicine, 10(1), 8-14. https://doi.org/10.11648/j.ajcem.20221001.12

Copy | Download

ACS Style

Okete James Agada; Oku Enewan Esien; Asor Joseph Ele; Eme Effiong Etta. Appraisal of Therapeutic Impact of One Round of Mass Praziquantel Administration (MPA) on Urinogenital Schistosomiasis in Benue State, Nigeria. Am. J. Clin. Exp. Med. 2022, 10(1), 8-14. doi: 10.11648/j.ajcem.20221001.12

Copy | Download

AMA Style

Okete James Agada, Oku Enewan Esien, Asor Joseph Ele, Eme Effiong Etta. Appraisal of Therapeutic Impact of One Round of Mass Praziquantel Administration (MPA) on Urinogenital Schistosomiasis in Benue State, Nigeria. Am J Clin Exp Med. 2022;10(1):8-14. doi: 10.11648/j.ajcem.20221001.12

Copy | Download

@article{10.11648/j.ajcem.20221001.12,
  author = {Okete James Agada and Oku Enewan Esien and Asor Joseph Ele and Eme Effiong Etta},
  title = {Appraisal of Therapeutic Impact of One Round of Mass Praziquantel Administration (MPA) on Urinogenital Schistosomiasis in Benue State, Nigeria},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {10},
  number = {1},
  pages = {8-14},
  doi = {10.11648/j.ajcem.20221001.12},
  url = {https://doi.org/10.11648/j.ajcem.20221001.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20221001.12},
  abstract = {Preventive chemotherapy through mass administration of praziquantel is the current global schistosomiasis control strategy recommended by the World Health Organization (WHO). We aimed to assess therapeutic impact of one round of mass praziquantel treatment on prevalence and intensity of Schistosoma haematobium infection. Longitudinal studies were carried out between March and November, 2018 in Katsina-Ala, Benue State, Nigeria following one round of mass praziquantel administration by the NTDs unit of CDC, Benue State in December, 2017. A total of 3,810 pupils, aged 5-19 years old were recruitedat baseline. Prevalence and intensity were determined using standard laboratory procedures for three successive phases (phase 1- three months; phase 2- six months and phase 3- nine months post treatment periods). Overall treatment coverage was 64.86%. Prevalence of infection was recorded in all the 3 phases, with the first phase having the highest prevalence (12.30%) followed by the third phase (9.12%) and the second phase (7.60%), the difference been significant (P < 0.05). The highest intensity of infection (16 ova/ 10 ml urine) was observed in the first phase, followed by the third phase (15.10 ova/10 ml urine) and the second phase (11 ova/ 10 ml urine). More males were infected than females. Prevalence and intensity were higher in untreated pupils than treated pupils in all the survey phases. The studies therefore, call for repeated mass treatment and integrated control measures to be adopted for total elimination of schistosomiasis.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Appraisal of Therapeutic Impact of One Round of Mass Praziquantel Administration (MPA) on Urinogenital Schistosomiasis in Benue State, Nigeria
AU  - Okete James Agada
AU  - Oku Enewan Esien
AU  - Asor Joseph Ele
AU  - Eme Effiong Etta
Y1  - 2022/01/24
PY  - 2022
N1  - https://doi.org/10.11648/j.ajcem.20221001.12
DO  - 10.11648/j.ajcem.20221001.12
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 8
EP  - 14
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20221001.12
AB  - Preventive chemotherapy through mass administration of praziquantel is the current global schistosomiasis control strategy recommended by the World Health Organization (WHO). We aimed to assess therapeutic impact of one round of mass praziquantel treatment on prevalence and intensity of Schistosoma haematobium infection. Longitudinal studies were carried out between March and November, 2018 in Katsina-Ala, Benue State, Nigeria following one round of mass praziquantel administration by the NTDs unit of CDC, Benue State in December, 2017. A total of 3,810 pupils, aged 5-19 years old were recruitedat baseline. Prevalence and intensity were determined using standard laboratory procedures for three successive phases (phase 1- three months; phase 2- six months and phase 3- nine months post treatment periods). Overall treatment coverage was 64.86%. Prevalence of infection was recorded in all the 3 phases, with the first phase having the highest prevalence (12.30%) followed by the third phase (9.12%) and the second phase (7.60%), the difference been significant (P < 0.05). The highest intensity of infection (16 ova/ 10 ml urine) was observed in the first phase, followed by the third phase (15.10 ova/10 ml urine) and the second phase (11 ova/ 10 ml urine). More males were infected than females. Prevalence and intensity were higher in untreated pupils than treated pupils in all the survey phases. The studies therefore, call for repeated mass treatment and integrated control measures to be adopted for total elimination of schistosomiasis.
VL  - 10
IS  - 1
ER  -

Copy | Download